Explore more
News
FDA asks Sarepta to stop shipping gene therapy
Digest more
Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.
Key Takeaways Sarepta Therapeutics shares were down roughly 17% late Friday morning.The tumble followed a report that a third ...
Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...
WCMH Columbus on MSN1d
Sarepta Therapeutics lays off 500 employees amid FDA investigation, including 80 in ColumbusSarepta Therapeutics announced it is laying off nearly 500 employees this week, including 80 at its Easton location.
Shares of Sarepta Therapeutics declined 17% in early trading on Friday after another patient who had received an experimental ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the ...
The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...
Stocktwits on MSN5h
GlucoTrack, Sarepta, TNF Pharma Dominate Weekly Retail Health Care Buzz — Here’s WhyRetail chatter spiked last week as investors piled into three healthcare stocks: GlucoTrack, Sarepta Therapeutics, and TNF Pharmaceuticals, which recorded the highest increases in message volume among ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback